Prof Fran Balkwill
Deputy Lead, Centre for Tumour Microenvironment
Barts Cancer Institute
Queen Mary University of London
Queen Mary University of London
Research
cancer, tumour microenvironment, multi-cellular models, ovarian cancer, extracellular matrix, immunotherapy
Interests
The interest and experience of my laboratory relates to complex multi-cellular models MCMs of the tumour microenvironment, especially in ovarian cancer. Having completed a multi-level deconstruction of ovarian cancer metastases, we have begun to reconstruct 3D multi-cellular models of these metastases using primary adipocytes, fibroblasts, mesothelial cells, monocytes and malignant cells. We are also currently working to vascularise these MCMs. We are using the models to understand cell cell communication in the tumour microenvironment, test new biological therapies and study sensitivity and resistance to T cell killing.Grants
Grants of specific relevance to Predictive in vitro Models
REMODEL - ERC AdG 2021 Frances BalkwillFran Balkwill
£2,154,257 EPSRC - EU Scheme
01-10-2022 - 30-09-2027
Evaluation of the cytotoxic function of the AZ CAR-T cell products by employing human in vitro 3 D multicellar models of high grade serous ovarian cancerBeatrice Malacrida and Fran Balkwill
£119,779 AstraZeneca UK Limited
12-09-2024 - 11-09-2025
Studying immune repertoire as an indicator for response to immunotherapy treatment in High-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£24,208 CR-UK Cancer Research UK
15-02-2024 - 14-02-2025
Targeting immune cells to improve response the chemotherapy in high-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£52,374 Barts and the London Charity
01-04-2023 - 31-03-2024
CRUK City of London Centre 2020 Consumables AwardFran Balkwill
£15,000 University College London
03-12-2020 - 31-03-2021
CHILL COGNITION new versionChristopher Griffiths and Fran Balkwill
£302,743 Barts and the London Charity
01-09-2020 - 01-09-2024
Interplay between ovarian cancer stem cells and the tumour microenvironmentFran Balkwill
£230,324 Ovarian Cancer Research Alliance (USA)
01-01-2020 - 31-12-2023
Immunotheraphy and clear cell ovarian cancerFran Balkwill
£290,799 MRC Medical Research Council
01-01-2019 - 30-06-2022
The effect of chemotherapy on Macrophage subpopulations in high-grade ovarian serous carcinomaFran Balkwill
£20,000 Wellbeing of Women
03-12-2018 - 30-11-2020
Targeting the innate immune system in high grade serous ovarian cancerFran Balkwill
£1,924,190 CR-UK Cancer Research UK
01-10-2018 - 31-10-2024
Exploring novel immunotherapy combinations for the treatment of lung cancer- also look at Project 380880Maria Castellano Sanchez and Fran Balkwill
£45,000 ACERTA
26-03-2018 - 15-03-2021
Advanced solid tissue models of T cell migration and activityFran Balkwill
£100,028 BBSRC Biotechnology and Biological Sciences Research Council
02-10-2017 - 25-03-2022
Advanced solid tissue models of T-cell migration and activityFran Balkwill
£32,000 GSK GlaxoSmithKline UK Ltd
01-10-2017 - 25-03-2022
Investigating the tumour extracellular matrix in the inhibition of anti-tumour imunityOliver Pearce and Fran Balkwill
£113,891 UCB Pharma SPRL
01-10-2017 - 28-02-2021
Targeting the peritoneal tumour microenvironment of high grade serous ovarian cancer CIFG1C9RFran Balkwill
£1,652,914 CR-UK Cancer Research UK
01-08-2017 - 31-03-2019
The effects of neo-adjuvant chemotherapy on myleoid cells in high-grade serous ovarian cancer metastases CIFG1E4RFran Balkwill
£313,427 Wellcome Trust
01-05-2016 - 30-04-2019



